Key result
A low hemoglobin-to-creatinine ratio at discharge in STEMI patients predicted higher one-year all-cause mortality and was an independent risk marker.
Why the study?
Anemia and renal impairment predict adverse outcomes in ACS, and this study aimed to evaluate the prognostic value of the hemoglobin-to-creatinine ratio at discharge in STEMI patients.
Does a low hemoglobin-to-creatinine (Hb/Cr) ratio at discharge predict increased one-year mortality and adverse outcomes in patients with STEMI?
Observational (n=11,236)
Does a low hemoglobin-to-creatinine (Hb/Cr) ratio at discharge predict increased one-year mortality and adverse outcomes in patients with STEMI?
The hemoglobin-to-creatinine ratio at discharge is a simple, independent predictor of one-year mortality and adverse outcomes in patients with STEMI.
Answers are grounded in this paper and cite their sources.
Low Hb/Cr ratio may flag higher one-year mortality risk after STEMI discharge; hypothesis-generating and requires prospective validation before clinical use.
Background/Objectives: Anemia and renal impairment are key predictors of adverse outcomes in acute coronary syndromes (ACSs). The hemoglobin-to-creatinine (Hb/Cr) ratio combines these parameters into a simple index. This study aimed to evaluate its prognostic value at discharge in patients with ST-elevation myocardial infarction (STEMI). Methods: The primary endpoint was one-year all-cause mortality; secondary endpoints included major bleeding and the composite of all-cause mortality or reinfarction. Optimal Hb/Cr cut-off values were identified using Liu’s method. Multivariable logistic regression and propensity score matching were used to assess associations with outcomes. Results: We analyzed 11,236 STEMI patients from the PRAISE registry with available hemoglobin and creatinine values at discharge. The optimal cut-points were 13.68 for mortality and 14.42 for secondary endpoints. Patients were stratified into low (<13.68; 26.5%) and high (≥13.68; 73.5%) Hb/Cr groups. The low Hb/Cr group was older, had more comorbidities, and received less intensive therapy. At one year, low Hb/Cr patients had significantly higher rates of all-cause mortality (8.7% vs. 2.4%), major bleeding (5.0% vs. 2.4%), and the composite outcome (11.5% vs. 4.9%). In the multivariate logistic regression, the Hb/Cr ratio was inversely associated with all outcomes, namely all-cause mortality (odds ratio [OR] 0.94; 95% confidence interval [CI]: 0.92–0.96), major bleeding (OR 0.96; 95% CI: 0.94–0.97), and the composite endpoint (OR 0.93; 95% CI: 0.91–0.96). The Hb/Cr ratio outperformed hemoglobin and creatinine alone in predicting mortality (AUC 0.684 vs. 0.649 and 0.645; p < 0.001). Conclusions: The Hb/Cr ratio is independently associated with one-year adverse outcomes in STEMI and may serve as a simple marker of increased vulnerability. Prospective studies are needed to validate its clinical utility.
No takes yet. Share an insight, caveat, or question.
Spadafora et al. (2025) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=11,236). Low hemoglobin-to-creatinine (Hb/Cr) ratio (<13.68) vs. High Hb/Cr ratio (≥13.68) was evaluated on one-year all-cause mortality (OR 0.94, 95% CI 0.92-0.96). A low hemoglobin-to-creatinine ratio at discharge in STEMI patients predicted higher one-year all-cause mortality and was an independent risk marker.
Synapse has enriched 10 related papers. Consider them for comparative context: